Loading...
•
Dec 31, 2023
Kiniksa Q4 2023 Earnings Report
Kiniksa meaningfully advanced its business through robust ARCALYST net product revenue and collaboration profit growth.
Key Takeaways
Kiniksa reported strong Q4 2023 results driven by ARCALYST net product revenue growth. The company anticipates continued growth with ARCALYST in recurrent pericarditis and expects its commercial performance to contribute to a strong financial position.
ARCALYST Q4 2023 net product revenue was $71.2 million.
ARCALYST full-year 2023 net product revenue was $233.2 million.
ARCALYST 2024 net product revenue is expected to be $360 - $380 million, representing ~59% year-over-year growth at the midpoint.
Cash reserves of $206.4 million are expected to fund operations into at least 2027.
Forward Guidance
Kiniksa expects ARCALYST 2024 net product revenue to be $360 - $380 million, representing ~59% year-over-year growth at the midpoint, and cash reserves of $206.4 million expected to fund operations into at least 2027.
Positive Outlook
- ARCALYST 2024 net product revenue expected to be $360 - $380 million, representing ~59% year-over-year growth at the midpoint
- Cash reserves of $206.4 million expected to fund operations into at least 2027
- Significant growth remains with ARCALYST in recurrent pericarditis
- Expect to help an increasing number of patients in the years ahead
- Robust commercial performance to contribute to our strong financial position and ability to drive growth across our business
Challenges Ahead
- Delays or difficulty in enrollment of patients in clinical trials
- Potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials
- Inability to replicate results from earlier clinical trials or studies
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...